

[Generate Collection](#)[Print](#)

## Search Results - Record(s) 2 through 11 of 22 returned.

---

2. 6440423. 02 Aug 99; 27 Aug 02. Mutant enterotoxin effective as a non-toxic oral adjuvant. Clements; John D., et al. 424/236.1; 424/184.1 424/200.1 424/234.1 424/235.1 424/240.1 424/241.1 424/257.1 424/261.1 424/278.1 424/282.1 514/2 530/350 530/820 530/825. A61K039/02 A61K039/108 A61K039/106 A61K045/00 C07K001/00.

---

3. 6436407. 04 Aug 99; 20 Aug 02. Mutant enterotoxin effective as a non-toxic adjuvant. Clements; John D., et al. 424/208.1; 424/184.1 424/200.1 424/234.1 424/235.1 424/236.1 424/278.1 424/282.1 530/350 530/825. A61K039/21 A61K039/02 A61K045/00 A61K039/00 A61K001/00.

---

4. 6419932. 19 Aug 97; 16 Jul 02. Antigen of hybrid M protein and carrier for Group A streptococcal vaccine. Dale; James B.. 424/244.1; 424/184.1 424/185.1 424/192.1 424/237.1 435/320.1 435/69.3 530/300 530/350 536/23.1 536/23.4 536/23.7. A61K039/09 A61K039/00 A61K038/00 C07H021/04.

---

5. 6413523. 23 Feb 95; 02 Jul 02. Pharmaceutical composition of escherichia coli heat-labile enterotoxin adjuvant and methods of use. Clements; John D. 424/241.1; 424/197.11 424/234.1 424/236.1 424/93.1 424/93.48. A61K039/108 A61K039/02 A61K039/385.

---

6. 6372221. 12 Dec 97; 16 Apr 02. Immunogenic constructs comprising flaviviruses or flavivirus derivatives. Mannhalter; Josef W., et al. 424/196.11; 424/197.11 424/201.1 424/218.1 424/239.1 424/281.1 424/93.3 424/93.6. A61K039/295 A61K039/385.

---

7. 6232116. 07 Jun 95; 15 May 01. Oral administration of pneumococcal antigens. Briles; David E., et al. 435/320.1; 424/244.1. A61K039/09 C12N015/00.

---

8. 6231870. 02 Jun 95; 15 May 01. Oral administration of pneumococcal antigens. Briles; David E., et al. 424/244.1; 435/253.4. A61K039/09 C12N015/00 C12N001/20.

---

9. 6043057. 22 Apr 97; 28 Mar 00. Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides. Holmgren; Jan, et al. 435/69.7; 435/252.3 435/320.1 530/350 536/23.4. C07K019/00 C12N015/62.

---

10. 6042838. 19 May 95; 28 Mar 00. immunogenic compositions for mucosal administration of pneumococcal surface protein A (PspA). Briles; David E., et al. 424/244.1; 424/184.1 424/237.1 435/69.1. A61K039/09 A61K039/00 C12P021/06.

---

11. 6040421. 16 Jun 98; 21 Mar 00. Escherichia coli O157:H7 epithelial adhesion and vaccine. Tarr; Phillip I., et al. 530/300; 424/184.1 424/185.1 424/241.1 424/242.1 424/257.1 530/350 530/825. A61K038/00 A61K039/02 A61K039/108 A61K039/00 C07C245/00.

---

[Generate Collection](#)[Print](#)

Terms	Documents
5182109	22

[Generate Collection](#)[Print](#)**Search Results - Record(s) 12 through 21 of 22 returned.**

---

12. 6033673. 18 Mar 98; 07 Mar 00. Double mutant enterotoxin for use as an adjuvant. Clements; John D.. 424/236.1; 424/184.1 424/241.1 424/278.1 424/282.1 424/832 424/9.2 514/885. A61K039/02 A61K039/108 A61K045/00 X61K039/00.

---

13. 6027734. 30 Sep 94; 22 Feb 00. Mucosal administration of pneumococcal antigens. Briles; David E., et al. 424/244.1; 424/184.1 424/282.1 424/93.44. A61K039/09 A61K039/00 A01N063/00.

---

14. 6019982. 26 Aug 94; 01 Feb 00. Mutant enterotoxin effective as a non-toxic oral adjuvant. Clements; John D., et al. 424/236.1; 424/184.1 424/200.1 424/208.1 424/234.1 424/235.1 424/240.1 424/241.1 424/261.1 435/91.4. A61K039/00 A61K039/38 A61K039/02 C12N015/64.

---

15. 5919463. 16 Oct 95; 06 Jul 99. Clostridium difficile toxins as mucosal adjuvants. Thomas, Jr.; William D., et al. 424/239.1; 424/184.1 424/192.1 424/234.1 424/236.1 424/247.1 424/278.1 424/94.6 514/2 530/300 530/350 530/825. A61K039/08 A61K038/46.

---

16. 5798260. 26 Mar 97; 25 Aug 98. Escherichia coli O157:H7 epithelial adhesin. Tarr; Phillip I., et al. 435/252.3; 435/320.1 536/23.7. C12N001/21 C12N015/63 C07H021/04.

---

17. 5759992. 07 Mar 96; 02 Jun 98. Immunotherapeutic agent derived from bacteria and method for its manufacture. Platt; David. 514/2; 424/248.1 424/257.1 435/243 435/252.33 435/253.1 435/849 435/863 514/21 514/885 530/412 530/413 530/414 530/418 530/427. A61K038/00 C12N001/00 A23J001/00.

---

18. 5679354. 21 May 91; 21 Oct 97. Matrix with immunomodulating activity. Morein; Bror, et al. 424/278.1; 514/25. A61K047/08 A61K045/00.

---

19. 5527770. 31 Aug 94; 18 Jun 96. Immunotherapeutic agent derived from bacteria. Platt; David. 514/2; 424/248.1 424/257.1 435/243 435/252.33 435/253.1 435/849 435/863 514/21 514/885 530/412 530/413 530/414 530/418 530/427. A61K038/00 C12N001/00 A23J001/00.

---

20. 5506129. 28 Nov 94; 09 Apr 96. Virus production. Sangar; David V.. 435/239; 424/184.1 424/226.1 435/235.1 435/236 435/237. C12N007/00 C12N007/01 C12N007/04 C12N007/08.

---

21. 5462734. 22 Mar 93; 31 Oct 95. Bovine herpesvirus vaccine and method of using same. Letchworth, III; Geoffrey J., et al. 424/229.1; 424/813 435/69.3 530/395. A61K039/245 C07K014/03.

---

[Generate Collection](#)[Print](#)

Terms	Documents
5182109	22

[Previous Page](#)    [Next Page](#)

**Search Results - Record(s) 2 through 11 of 22 returned.**

---

2. 6440423. 02 Aug 99; 27 Aug 02. Mutant enterotoxin effective as a non-toxic oral adjuvant. Clements; John D., et al. 424/236.1; 424/184.1 424/200.1 424/234.1 424/235.1 424/240.1 424/241.1 424/257.1 424/261.1 424/278.1 424/282.1 514/2 530/350 530/820 530/825. A61K039/02 A61K039/108 A61K039/106 A61K045/00 C07K001/00.

---

3. 6436407. 04 Aug 99; 20 Aug 02. Mutant enterotoxin effective as a non-toxic adjuvant. Clements; John D., et al. 424/208.1; 424/184.1 424/200.1 424/234.1 424/235.1 424/236.1 424/278.1 424/282.1 530/350 530/825. A61K039/21 A61K039/02 A61K045/00 A61K039/00 A61K001/00.

---

4. 6419932. 19 Aug 97; 16 Jul 02. Antigen of hybrid M protein and carrier for Group A streptococcal vaccine. Dale; James B.. 424/244.1; 424/184.1 424/185.1 424/192.1 424/237.1 435/320.1 435/69.3 530/300 530/350 536/23.1 536/23.4 536/23.7. A61K039/09 A61K039/00 A61K038/00 C07H021/04.

---

5. 6413523. 23 Feb 95; 02 Jul 02. Pharmaceutical composition of escherichia coli heat-labile enterotoxin adjuvant and methods of use. Clements; John D. 424/241.1; 424/197.11 424/234.1 424/236.1 424/93.1 424/93.48. A61K039/108 A61K039/02 A61K039/385.

---

6. 6372221. 12 Dec 97; 16 Apr 02. Immunogenic constructs comprising flaviviruses or flavivirus derivatives. Mannhalter; Josef W., et al. 424/196.11; 424/197.11 424/201.1 424/218.1 424/239.1 424/281.1 424/93.3 424/93.6. A61K039/295 A61K039/385.

---

7. 6232116. 07 Jun 95; 15 May 01. Oral administration of pneumococcal antigens. Briles; David E., et al. 435/320.1; 424/244.1. A61K039/09 C12N015/00.

---

8. 6231870. 02 Jun 95; 15 May 01. Oral administration of pneumococcal antigens. Briles; David E., et al. 424/244.1; 435/253.4. A61K039/09 C12N015/00 C12N001/20.

---

9. 6043057. 22 Apr 97; 28 Mar 00. Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides. Holmgren; Jan, et al. 435/69.7; 435/252.3 435/320.1 530/350 536/23.4. C07K019/00 C12N015/62.

---

10. 6042838. 19 May 95; 28 Mar 00. immunogenic compositions for mucosal administration of pneumococcal surface protein A (PspA). Briles; David E., et al. 424/244.1; 424/184.1 424/237.1 435/69.1. A61K039/09 A61K039/00 C12P021/06.

---

11. 6040421. 16 Jun 98; 21 Mar 00. Escherichia coli O157:H7 epithelial adhesion and vaccine. Tarr; Phillip I., et al. 530/300; 424/184.1 424/185.1 424/241.1 424/242.1 424/257.1 530/350 530/825. A61K038/00 A61K039/02 A61K039/108 A61K039/00 C07C245/00.

---

Terms	Documents
5182109	22

**Search Results - Record(s) 22 through 22 of 22 returned.**

22. 5182109. 10 Apr 89; 26 Jan 93. Vaccine preparation comprising a bacterial toxin adjuvant. Tamura; Shinichi, et al. 424/197.11; 424/184.1 424/192.1 424/193.1 424/202.1 424/203.1 424/209.1 424/210.1 424/212.1 424/215.1 424/218.1 424/219.1 424/227.1 424/234.1 424/236.1 424/237.1 424/240.1 424/241.1 424/254.1 424/257.1 424/261.1 424/264.1 424/282.1. A61K039/02 A61K039/12.

Terms	Documents
5182109	22

[Previous Page](#)    [Next Page](#)